KRAS and neoplasm: The authors went on to demonstrate that combination treatment with the MEK inhibitor AZD6244 and c-MET inhibitor crizotinib led to the synergistic inhibition of KRAS-mutated CRC tumor growth in both HCT116 and SW620 xenograft mouse models [76].